Buntanetap for Alzheimer's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests buntanetap, a medication, on people with mild to moderate Alzheimer's disease. It aims to find out if different doses of the medication are effective and safe. Participants will take the medication daily for a few months, and their progress will be monitored through various assessments.
Do I need to stop my current medications to join the trial?
The trial requires that your current medications be stable for at least 4 weeks before screening. You may need to stop taking strong and moderate CYP3A4 inhibitors or inducers.
Are You a Good Fit for This Trial?
This trial is for people aged 55-85 with mild to moderate Alzheimer's, as per NIA criteria. They must have a study partner, be in good health without diseases affecting the study, and not at risk of self-harm. Women of childbearing age need a negative pregnancy test and agree to contraception; men must also agree to contraceptive measures.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daily administration of buntanetap/Posiphen or placebo for 12 weeks, with in-clinic visits for safety assessments and psychometric tests
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Buntanetap
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Annovis Bio Inc.
Lead Sponsor